Collection of full-length human cDNA clones in mammalian expression vectors to expaned to 35,000, representing one of the world's largest collections
Xantos Biomedicine, a functional biology and drug discovery company, announces that it has expanded its collection of full-length human cDNA clones in mammalian expression vectors to 35,000, representing one of the world's largest collections. The Xantos covers individual cDNA expression plasmids from more than 24,000 distinct human gene loci.
Redundant clones frequently represent alternate splice products.
Thus the cDNA clones collection comprises a significant portion of the human genome. It is continually being expanded to represent the entire transcribed human genome.
The collection contains a variety of sub groups relevant for drug development including drugable targets, secreted and receptor proteins.
Furthermore, since sequence information is instantly available it means that cDNAs can be rapidly linked to biological function.
In less than a year Xantos has expanded its clone collection from 20,000 to 35,000, enabling the company to improve the speed and therefore cost with which it can carry out genome-wide functional target identification and validation in XantoScreen.
The entire collection can be screened in less than a month on this automated disease cellular screening platform.
Ulrich Brinkmann, Xantos CSO, commented: "Xantos has already started to reap the benefits from this cDNA collection in its metabolic disease programme, where it has identified a number of novel functionally-validated targets with relevance in diabetes and obesity.
"Likewise a number of unique secreted proteins that play a role in angiogenesis have been identified." Both the Xantos clone collection and disease-specific cDNA libraries are available for use through collaborative partnerships or by customers on a fee-for-service basis.
